Genmab AS (LTS:0MGB) Net Income From Continuing Operations : kr8,845 Mil (TTM As of Mar. 2025)

View and export this data going back to 2010. Start your Free Trial

What is Genmab AS Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Genmab AS's net income from continuing operations for the three months ended in Mar. 2025 was kr1,683 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was kr8,845 Mil.

Genmab AS Net Income From Continuing Operations Historical Data

The historical data trend for Genmab AS's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS Net Income From Continuing Operations Chart

Genmab AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Income From Continuing Operations

Get a 7-Day Free Trial

5,967.66

3,925.31

7,019.97

5,720.29

9,105.83

Genmab AS Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															1,708.09	2,098.61	1,890.55	3,172.50	1,683.43

Genmab AS Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr8,845 Mil.

Genmab AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (LTS:0MGB) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

GNMSF:USA GMAB:USA GMABc:UK GMAB:Denmark GE91:Germany GMAB:Austria

Address

Carl Jacobsens Vej 30, Valby, DNK, 2500

Website

https://www.genmab.com

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab AS Headlines

No Headlines